Brookline Capital Acquisition Corp.
BCACU
NASDAQ Capital Market23.20
USD
+13.91
- -
CIK
0001814140
ISIN
US11374E2037
CUSIP
11374E203
Return %
Stock
S&P500
1Y
127.45
18.21
3Y
126.78
64.38
5Y
126.78
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James Jiayuan Tong
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- DE United States of America 10017
- IPO Date
- Jan 29, 2021
- CIK
- 0001814140
- Similar Companies
- Business
- Brookline Capital Acquisition Corp. Brookline Capital Acquisition Corp. is a blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company focuses on targets primarily in the life sciences sector, particularly in the United States and Europe; it does not have significant independent operations, products, or services beyond identifying and pursuing such a transaction with up to $57.5 million in gross proceeds from its January 2021 initial public offering of 5.75 million units priced at $10.00 each on Nasdaq under the ticker BCACU. Brookline Capital Acquisition Corp. was incorporated in 2020 and is headquartered at 280 Park Avenue, Suite 43W, New York, New York. In a major development, the company completed a reverse merger business combination with clinical-stage biopharmaceutical firm Apexigen, Inc. in July 2022, following a definitive agreement announced in March 2022; the transaction valued Apexigen at $205 million net equity, raised approximately $73 million in gross proceeds including a $15 million PIPE and up to $50 million committed equity facility from Lincoln Park Capital, and resulted in the combined entity renaming to Apexigen, Inc. (Nasdaq: APGN) with Brookline's units (BCACU), common stock (BCAC), and warrants (BCACW) undergoing symbol and CUSIP changes or suspension.
Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021
Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering
Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering